Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

INDIANAPOLIS, Feb. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced its financial results for the fourth quarter of 2022. "2023 is an inflection point for Lilly - a chance to ...

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite contro ...

Cost control and the advancement of its solid Phase III pipeline will be critical to long-term success. Eli Lilly has 7 molecules in Phase III development, 22 molecules in Phase II development and ...

We are increasing Eli Lilly’s fair value estimate to $500 from $450 following solid fourth-quarter results with robust sales from diabetes drug Mounjaro and strong pipeline advancements running ...

Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer’s disease, ALS and other brain diseases, CEO David Ricks said.

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so. Trading at $852 per ...

Lilly has 11 obesity drugs in its pipeline and wants to develop more ... Eli Lilly will invest $4.5 billion to ... Any new advances could help Lilly become the first trillion ...